EnteroBiotix expands microbial therapeutics manufacturing premises


The company's footprint at Scotland's Strathclyde Business Park is set to expand to beyond 20,000 sqft

EnteroBiotix, a biopharmaceutical company, has announced the completion of a purpose-built facility at Strathclyde Business Park, Glasgow, for the manufacturing and quality control of its microbial therapeutics, and an expansion of its corporate offices to support an increased headcount. The expansion follows a $21.5m Series A fundraising round in September.

The company's footprint at Scotland's Strathclyde Business Park is set to expand to beyond 20,000 sqft. The facility is designed to meet key regulatory requirements for biologics production and analytical activities. To accommodate the company’s significantly increased headcount and R&D requirements, it will also be increasing its current office, lab, and warehouse space.

Dr James McIlroy, CEO at EnteroBiotix, said: “Our new facility and overall site expansion is another significant milestone on our mission to transform the lives of patients through our orally delivered medicinal products enhancing the gut microbiome. Offering best-in-class capabilities, it will support the high quality, safe and consistent manufacturing and quality control of both our own and partnered programmes. As we extend our capacity and team during this exciting phase, we are determined to change the standard of care for patients battling debilitating diseases, including cancer, associated with the microbiome.”

Rosemary Hill, Director at Strathclyde Business Park: “Strathclyde Business Park provides great access to a skilled local workforce and is Scotland’s leading business location. We are delighted that yet another high calibre company has significantly expanded its premises in one of Scotland’s most inspirational working environments. This is further testament to the outstanding quality of Scotland’s thriving life sciences ecosystem.”

Sign up for your free email newsletter

The company says its product portfolio has potential applicability across multiple disease areas including immuno-oncology and diseases of the liver-brain axis.

The facility was designed and built by Cleanroom Construction Company.